Troubled Bioglan Pharma has put itself up for sale after revealing that a review of its controversial interim profits announcement had resulted in the loss increasing by £10.9m to £45.6m for the six months to 31 July. Terry Sadler, chief executive, said there was a 50/50 chance of sale prior to Christmas.